Abstract PO2-19-09: INAVO122: a Phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients with PIK3CA-mutated, HER2-positive advanced breast cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Randomized trial assesses efficacy and safety of inavolisib in advanced HER2+ cancer, indicating potential treatment advantage.

Efficacy in progression-free survival was evaluated, with patients receiving either inavolisib or placebo along with standard treatments.
Primary endpoint analysis utilized a stratified log-rank test at a significance level of 5%, emphasizing statistical rigor.
Maintenance phase involves randomization to inavolisib or placebo with standard combination therapies, reflecting a comprehensive treatment strategy in advanced disease setting around 230 patients planned for accrual by July 2023 interpretation from the enrollment data . Search for certain outcomes, including safety, will significantly impact treatment decisions and patient management in clinical settings.

Swain et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark